July 1, 2008 – Echo Therapeutics, Inc. (OTCBB: ECTE) announced that it has initiated a clinical study of its Symphony™ Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008. Echo’s non-invasive Symphony tCGM System consists of its Prelude™ SkinPrep System, which incorporates patented and leading-edge skin permeation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo’s Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device... [PDF] Echo Therapeutics' Press Release -
Thursday, July 10, 2008
Echo Therapeutics : Clinical Study of Its Symphony™ Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
July 1, 2008 – Echo Therapeutics, Inc. (OTCBB: ECTE) announced that it has initiated a clinical study of its Symphony™ Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008. Echo’s non-invasive Symphony tCGM System consists of its Prelude™ SkinPrep System, which incorporates patented and leading-edge skin permeation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo’s Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device... [PDF] Echo Therapeutics' Press Release -
